Physician profile
Shadrach Smith
NPI 1093770299
$27,403.44
in general payments reported to CMS, 2019-2025
59 companies · $13K in 2025
The $13K reported for 2025 was more than what 99% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,174 · 2020: $1,601 · 2021: $2,337 · 2022: $2,181 · 2023: $2,158 · 2024: $2,618 · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $11K · Food and Beverage: $7,284 · Education: $26.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,800.00 |
| Food and Beverage | $7,283.96 |
| Education | $26.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $12,633.39 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Novo Nordisk INC | $3,973.54 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,719.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $901.96 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $786.87 | 2021-2025 | Vraylar, Linzess, Viberzi |
| Abbott Laboratories | $759.62 | 2019-2025 | Freestyle Libre 3, Proclaim, Eterna |
| Pfizer INC. | $654.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $597.94 | 2019-2025 | Belsomra, Steglatro, Verquvo |
| Janssen Pharmaceuticals, INC | $571.99 | 2019-2024 | Xarelto |
| Glaxosmithkline, LLC. | $506.44 | 2019-2025 | Trelegy Ellipta |
| Amgen INC. | $469.81 | 2019-2025 | Evenity, Krystexxa, Otezla |
| Astellas Pharma US INC | $435.40 | 2019-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $307.66 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $258.54 | 2023-2025 | Gemtesa |
| Bayer Healthcare Pharmaceuticals INC. | $252.49 | 2021-2025 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shadrach Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.